Parnaparin sodium — modern therapy options and prevention of venous thromboembolic complications

Close metadata

Recommended articles:

Lymphatic Outflow and Correction of Appropriate Disorders in Patients with Venous Thrombosis and Chronic Venous Disease. Journal of Venous Disorders. 2024;(1):26-31

Venous thromboembolic complications (VTEC) including pulmonary embolism and acute thrombosis of deep and superficial veins of the lower extremities are often observed in postoperative period. Low-molecular-weight heparin (LMWH) is a common remedy for prevention and treatment of VTEC due to high efficiency, safety, easy use and dosage. According to the modern literature data, LMWH is characterized by different effectiveness in relation to VTEC and risk of bleeding in patients after surgical and traumatological procedures, as well as in ones with severe forms of chronic venous diseases. However, their antithrombin activity varies significantly depending on mean molecular weight. The authors analyze LMWH action mechanism, pharmacokinetic and pharmacodynamic features of LMWH, in particular parnaparin sodium. Efficacy, safety and tolerability of this remedy for various forms of VTEC (superficial and deep vein thrombosis, thrombophlebitis, complicated forms of chronic venous diseases), its advantages for prevention of VTEC after various surgical and orthopedic interventions are considered.

Keywords:

deep vein thrombosis (DVT)

pulmonary embolism (PE)

superficial vein thrombosis

prevention and treatment of VTEC

low-molecular-weight heparin (LMWH)

sodium parnaparin (fluxum)

Authors:

Petrikov A.S.

Altai State Medical University;
Diagnostic Center of Altai Territory

SPIN RSCI: 4612-6452
Scopus AuthorID: 56771302600
ORCID: 0000-0002-6501-3289

Received:

30.07.2020

Accepted:

10.08.2020

List of references:

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease. CHEST journal. Official publication of the American college of chest physician. 2016;149(2):315-352. https://doi.org/10.1016/j.chest.2015.11.026
Bokeriia LA, Zatevakhin II, Kirienko AI, Andriiashkin AV, Andriiashkin VV, Arutiunov GP, Barinov VE, Bitsadze VO, Bodykhov MK, Britov AN, Butenko AV, Vavilova TV, Vorobeva NA, Voskanian IuE, Gavrilenko AV, Galstian GM, Gelfand BR, Giliarov MIu, Golubev GSh, Zamiatin MN. Russian Clinical Guidelines for the Diagnostics, Treatment andprevention VTE. Flebologiya. 2015;4(2):10-17. (In Russ.).
Kirienko AI, Andriyashkin VV, Zhuravleva AD. Low molecular weight heparins in the prevention and treatment of acute venous thrombosis. CONSILIUM MEDICUM. Prilozhenie «Hirurgiya». 2002;1:32-37 (In Russ.).
Hao C, Sun M, Wang H, Zhang L, Wang W. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21-39. https://doi.org/10.1016/bs.pmbts.2019.02.003
Bogachev VYu, Boldin BV, Rodionov SV. Low molecular weight heparins in phlebological practice: focus on parnaparin. Lechebnoe delo. 2019;2:80-89. (In Russ.). https://doi.org/10.24411/2071-5315-2019-12116
Bergan JJ, Bunke-Paquette N. The vein book. editors. 2nd ed. NY: Oxford University Press; 2014.
Camporese G, Bernardi E, Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vascular Health and Risk Management. 2009;5:819-831. https://doi.org/10.2147/vhrm.s3430
Directory Vidal. Medicines in Russia. Iz-vo «Vidal’ Rus»; 2020. (In Russ.).
Shafiq N, Malhotra S, Pandhi P, et al. A Randomized Controlled Clinical Trial to Evaluate the Efficacy, Safety, Cost-Effectiveness and Effect on PAI-1 Levels of the Three Low-Molecular-Weight Heparins — Enoxaparin, Nadroparin and Dalteparin. The ESCAPe-END Study. Pharmacology. 2006;78(3):136-143. https://doi.org/10.1159/000096484
Sturov NV. Clinical pharmacology of LMWH: the most important aspects. Trudnyj pacient. 2006;4(11):38-42. (In Russ.).
Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26(2):24-38. https://doi.org/10.1159/000217270
Ryazhenov VV, Gorokhova SG. Clinical and economic analysis of the use of low molecular weight heparins in routine clinical practice. Trudnyj pacient. 2012;10(6):12-15. (In Russ.).
Alexander JH, Singh KP. Inhibition of factor Xa: a potential target for the development of new anticoagulants. Am J Cardiovasc Drugs. 2005;5(5):279-290. https://doi.org/10.2165/00129784-200505050-00001
Dettori AG. Parnaparin: a review of its pharmacological profile and clinical application. Drugs Today. 1995;31(1):19-35.
Frampton JE, Faulds D. Parnaparin: a review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. Drugs. 1994;47(4):652-676. https://doi.org/10,2165/00003495-199447040-00007
McKeage K, Keating GM. Parnaparin, A review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders. Drugs. 2008;68(1):105-122. https://doi.org/10.2165/00003495-200868010-00007
Information about Fluxum in the state register of medicines. Link is active on 08/07/2020 https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=761148ee-0582-4581-b237-1d0bf7633a98&t=
Verhaeghe R. The use of low-molecular-weight heparins in cardiovascular disease. Acta Cardiol. 1998;53(1):15-21.
Palareti G, Legnani C, Bianchini B, Guazzaloca G, Maccaferri M, Marabini A, De Iaco P, Marcozzi S, Mancini L,Orlandi C Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecologic surgery patients. Int Angiol. 1989;8(1):47-52.
Dettori AG, Tagliaferri A, Dall’Aglio E, Pini M. Clinical pharmacology of a new low molecular weight heparin (alfa LMWH- Fluxum). Int Angiol. 1988;7(3):7-18.
Wong GC, Giugliano RP. Low-molecular-weight heparins for the treatment of acute coronary syndromes. Semin Vasc Med. 2003;3(4):391-402. https://doi.org/10,1055/c-2004-817703
Dettori AG, Babbini M. Human pharmacology of a low-molecularweight heparin (alfa-LMWH): an update. Med Res Rev. 1992;12(4):373-389. https://doi.org/10.1002/med.2610120404
Bugamelli S, Zangheri E, Montebugnoli M, Guerra L. Clinical use of parnaparin in major and minor orthopedic sugery: a review. Vascular Health and Risk Managerment. 2008;4(5):983-990. https://doi.org/10.2147/vhrm.s3253
Romeo G, Salanitri G, Catania G. Time-course of Anti-Xa effects of Calcium Heparin and Low-Molecular-Weight Heparin given S.C. Drugs Under Experimental and Clinical Research. 1988;14(6):423-427.
Morozov KM, Kolbin AS, Galankin TL A network meta-analysis of the efficacy of parnaparin for the prevention of venous thromboembolic complications during surgery. Tromboz, gemostaz i reologiya. 2018;73(1):31-39. (In Russ.). https://doi.org/10.25555/THR.2018.1.0821
Camporese G, Bernardi E, Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vascular Health and Risk Management. 2009;5:819-831. https://doi.org/10.2147/vhrm.s3430
Kolbin AS, Galankin TL. Pharmacoeconomic analysis of parnaparin (Fluxum) use for the prevention of venous thromboembolic events after surgery and for the treatment of thrombophlebitis of superficial veins. Klinicheskaya farmakologiya i terapiya. 2017;26(1); 66-71. (In Russ.).
Prevention of venous thromboembolic complications in traumatology and orthopedics: Russian clinical guidelines. Travmatologiya i ortopediya Rossii. 2012;(63):1-24. (In Russ.).
Krichevsky LA. Low-Molecular-Weight Heparins’ Role in Current Strategies for Controlling Blood Coagulation. Anesteziologiya i reanimatologiya. Medicinskaya reabilitaciya. 2015;15(116)-16(117):42-48. (In Russ.).
Kopenkin SS. Prevention of venous thromboembolic complications in traumas of locomotor system. Medicinskij sovet. 2016;10:143-147. (In Russ.). https://doi.org/10.21518/2079-701X-2016-10-143-147
Montebugnoli M, Bugamelli S, Calò P, Zangheri E, Ferrari P. Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. Clin Appl Thromb Hemost. 2007;13(3):249-258. https://doi.org/10.1177/1076029607302667
Chiapuzzo E, Orengo GB, Ottria G, A. Chiapuzzo, E. Palazzini, M. Fusillo. The use of low molecular weight heparins for post-surgical deep vein thrombosis prevention in orthopaedic patients. J Int Med Res. 1988;16(5):359-366. https://doi.org/10.1177/030006058801600505
Mascali F, Condorelli A, Salanitiri G, Palazzini E, Iani P. Postsurgery thromboembolism prevention by LMW heparin subcutaneous administration. Eur Rev Med Pharmacol Sci. 1988;10:135-141.
Salcuni PF, Azzarone M, Palazzini E. A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients. Curr Ther Res. 1988;43:824-831.
Bellosta R, Ferrari P, Luzzani L, Carugati C, Cossu L, Talarico M. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations. Angiology. 2007;58:316-322. https://doi.org/10.1177/0003319707301757
Notarbartolo A, Salanitri G, Davì G, Averna M, Barbagallo C, Catalano I. Low-molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Praxis. 1988;9(4):1-13.
Zinicola N, Cerruti R. Deep vein thrombosis of the lower limbs: results of long term treatment with a new low-molecular weight heparin. Farmaci e terapia. 1989;3:147-151.
Teoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clinical Trials Metaanal. 1993;28:215-225.
Vashist MG, Kapoor S, Dhingra A. Is low molecular weight heparin effective and safe in the management of deep vein thrombosis? A prospective randomized study. Ind Med Gaz. 2006;140:175-178.
Stoiko YuM, Kirienko AI, Ilyukhin EA, Lobastov KV, Chabbarov RG, Parikov MA, Khoriev NG, Zolotukhin IA, Andriyashkin VV, Karpenko AA, Fokin AA, Sushkov SA, Sapelkin SV, Suchkov IA, Krylov AYu, Ignatiev IM. Diagnostics and treatment of thrombophlebitis of superficial veins of the extremities. Recommendations of the Association of Phlebologists of Russia. Flebologiya. 2019;2(13):78-97. (In Russ.). https://doi.org/10.17116/flebo20191302178
Cosmi B, Fillippinni M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G; STEFLUX Investigators. A randomized double-blind study of low-molecular-weight heparin (parnaparine) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). Journal of Thrombosis and Haemostais. 2012;10(6):1026-1035. https://doi.org/0.1111/j.1538-787836.2012.04727.x
Galanaud J-P, Genty C, Sevestre M-A, Brisot D, Lausecker M, Gillet J-L, et al. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. Thrombosis and haemostasis. 2011;105(01):31-39. https://doi.org/10.1160/th10-06-0406
Cosmi B, Fillippinni M, Tonti D, Avruscio G, Ghirarduzzi A, Bucherini E, Camporese G, Imberti D, Palareti G., Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). Thromb Res. 2014;133(2):196-202. https://doi.org/10.1016/j.thromres.2013.12.005
Decousus H, Quéré I, Presles E, Becker F, Barrellier MT, Chanut M, Gillet JL, Guenneguez H, Leandri C, Mismetti P, Pichot O, Leizorovicz A. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. POST (Prospective Observational Superficial Thrombophlebitis) Study Group. Ann Intern Med. 2010;152(4):218-224. https://doi.org/10.7326/0003-4819-152-4-201002160-00006
Barco S, Pomero F, di Minno M, Tamborini Permunian E, Malato A, Pasca S, et al. Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow‐up study. Journal of Thrombosis and Haemostasis. 2017;15(11):2176-2183. https://doi.org/10.1111/jth.13840
Galanaud J, Bosson J, Genty C, Presles E, Cucherat M, Sevestre M, Quere I, Decousus H, Leizorovicz A. Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. Journal of Thrombosis and Haemostasis. 2012;10(6):1004-1011. https://doi.org/10.1111/j.1538-7836.2012.04704.x
Cannegieter SC, Horváth-Puhó E, Schmidt M, Dekkers OM, Pedersen L, Vandenbroucke JP, Sørensen HT. Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood. 2015;125(2):229-235. https://doi.org/10.1182/blood-2014-06-577783
Superficial thrombophlebitis treated by Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Archive of Internal Medicine. 2003;163(14):1657-1663. https://doi.org/10.1001/archinte.163.14.1657
Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitisof the leg. Cochrane Database of Systematic Reviews. 2013;4. https://doi.org/10.1002/14651858.cd004982.pub5
Beyer-Westendorf J. Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. ASH Education Program Book. 2017;1:223-230. https://doi.org/10.1182/asheducation-2017.1.223
Scovell SD. Phlebitis and thrombosis of the superficial lower extremity veins. 2017 [cited 2017 29.12]. Accessed March 2, 2019. https://www.uptodate.com/contents/phlebitis-and-thrombosis-of-the-superficial-lower-extremity-veins#H25234570
Verardi S, Ippoliti A, Pistolese GR. Antithrombotic treatment during acute inflammatory complications of patients affected by postphlebytic syndrome: LMW-heparin versus standard heparin. Int Angiol. 1988;7(3):33-40.
Sannazzari P. Low molecular weight heparin in the symptomatic treatment of chronic venous insufficiency: controlled double blind study vs calcium heparin. Panminerva Med. 1989 31(3):127-133.
Catania G, Salanitri T. Heparin therapy of post-phlebitic syndrome: results of a single-blind, clinical trial of parnaparin vs calcium heparin. Stampa Medica Europea. 1993;13:17-27.
Canova R, Celentano R, Gasbarrone L. Long-term treatment of patients with post-phlebitic syndrome by means of a new lmw heparin. NAM. 1993;9:318-324.
Della Marchina M, Renzi G, Renzi C, Palazzini E. Low molecular weight heparins in chronic venous insufficiency: controlled trial of parnaparin efficacy and tolerability. Br J Clin Res. 1993;4:29-36.
Di Stefano F, Giglio A, Vinci M. Low molecular weight heparins for long-term therapy of peripheral vascular disease. Curr Ther Res. 1988;44(1):1-10.
Verardi S, Casciani CU, Nicora E, et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 1988;7(3):19-24.
Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335. https://doi.org/10.1056/NEJM199505183322003
Prandoni P, Siragusa S, Girolami B, Fabris F. BELZONI Investigators Group. The incidence of heparininduced thrombocytopenia in medical patients treated with lowmolecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049-3054. https://doi.org/10.1182/blood-2005-03-0912
Sartori M, Favaretto E, Migliaccio L, Guazzaloca G, Legnani C, Palareti G, Cosmi B. The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis. Thromb Res. 2016;139:154-157. https://doi.org/10.1016/j.thromres. 2016.02.004

Close metadata